Elevated urinary transforming growth factor-β1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma

British Journal of Cancer

Volumn 76, Issue 2, 1997, Pages 244-250

  Tsai, J F ^a   Jeng, J E ^a   Chuang, L Y ^a   Yang, M L ^a   Ho, M S ^b   Chang, W Y ^a   Hsieh, M Y ^a   Lin, Z Y ^a   Tsai, J H ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Survival; Transforming growth factor 1; Urine; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; SURVIVAL TIME; TUMOR VOLUME; URINE LEVEL;

EID: 0030961335     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.369     Document Type: Article

References (34)

1. American Joint Committee on Cancer (1992) Manual for Staging of Cancer. JB Lippincott: Philadelphia
2. Bedossa P, Peltier E, Terris B, Franco D and Poynard T (1995) Transforming growth factor-beta 1 (TGF-β1) and TGF-β1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 21: 760-766
3. Bissell DM and Maher JJ (1996) Hepatic fibrosis and cirrhosis. In Hepatology: a Textbook of Liver Disease, Zakim D and Boyer TD. (eds). pp. 506-525, WB Saunders: Philadelphia
4. Chuang LY, Tsai JH, Yeh YH, Chang CC, Yeh HW, Guh JY and Tsai JF (1991) Epidermal growth factor-related transforming growth factors in the urine of patients wilh hepatocellular carcinoma. Hepatology 13: 1112-1116
5. Chuang LY, Hon WC, Yang ML, Chang CC and Tsai JF (1994) Urinary epidermal growth factor receptor-binding growth factors in the tumors of the digestive tract. Clin Biochem 27: 485-489
6. Colombo M (1995) Should patients with chronic viral hepatitis be screened for hepatocellular carcinoma? Viral Hepatitis Rev 1: 67-75
7. Coupes BM, Newstead CG, Short CD and Brenchley PEC (1994) Transforming growth factor β1 in renal allograft recipients. Transplantation 57: 1727-1731
8. Fausto N (1991) Multifunctional roles of transforming growth factor beta 1. Lab Invest 65: 497-499
9. Fausto N, Mead JE, Gruppuso PA and Braun L (1991) TGF-β in liver development. regeneration, and carcinogenesis. Ann NY Acad Sci 593: 231-242
10. Hsieh MY, Chen SC, Lu SN, Wang LY, Tsai JF, Chuang WL, Lin ZY and Chang WY (1996) Treatment of hepatocellular carcinoma smaller than 5 cm by transcatheter arterial chemoembolization. Kaohsiung J Med Sci 12: 274-278
11. Ito N, Kawata S, Tamura S, Takaishi K, Yabuuchi I, Matsuda Y, Nishioka M and Tarui S (1990) Expression of transforming growth factor-beta 1 mRNA in human hepatocellular carcinoma. Jpn J Cancer Res 81: 1202-1205
12. Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S, Yabuuchi I, Matsuda Y, Nishioka M and Tarui S (1991) Elevated levels of transforming growth factor-beta and its polypeptide in human hepatocellular carcinoma. Cancer Res 15: 4080-4083
13. Jeng JE and Tsai JF (1991) Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan. J Med Virol 34: 74-77
14. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observation. Am Stat Assoc 53: 457-458
15. Lee GH, Merlino G and Fausto N (1992) Development of liver tumors in transforming growth factor α transgenic mice. Cancer Res 52: 5162-5170
16. Nakao K, Nakata K, Mitsuoka S, Ohtsuru A, Ido A, Hatano M, Sato Y, Nakayama T, Shima M, Kusumoto Y, Koji T, Tamaoki T and Nagataki S (1991) Transforming growth factor β1 differentially regulates α-fetoprotein and albumin in HuH-7 human hepatoma cells, Biochem Biophys Res Commun 174: 1294-1299
17. Nishimura R, Okumura H, Noda K, Yasumitsu H and Umeda M (1986) High level of β type transforming growth factor activity in human urine obtained from cancer patients. Jpn J Cancer Res 77: 560-567
18. Pugh RN, Murray-Lyon IM, Dawson JL, Peitroni MC and Williams R (1973) Transection of the esophagus for bleeding esophageal varices. Br J Surg 60: 646-649
19. Ranganathan G, Lyons R, Jiang NS and Moses H (1987) Transforming growth factor β in normal human urine. Biochem Biophys Res Comm 148: 1503-1512
20. Roberts AB and Sporn MB (1990) The transforming growth factor betas. In Handbook of Experimental Pharmacology, Sporn MB and Roberts AB. (eds). Vol. 95, pp. 419-472. Springer: Heidelberg, Germany
21. Roberts AB, Thompson NL, Heine U, Flanders C and Sporn MB (1988) Transforming growth factor-beta: possible roles in carcinogenesis. Br J Cancer 57: 594-600
22. Sherlock S and Dooley J (1993) Disease of the Liver and Biliary System. pp. 503-531. Blackwell Scientific: Oxford
23. Sherwin SA, Twardzik DR, Bohn WH, Cockley KD and Todaro GJ (1983) High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer. Cancer Res 43: 403-107
24. Shirai Y, Kawata S, Ito N, Tamura S, Takaishi K, Kiso S, Tsushima H and Matsuzawa Y (1992) Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma. Jpn J Cancer Res 83: 676-679
25. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S and Matsuzawa Y (1994) Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma. Cancer 73: 2275-2279
26. Sox HC, Blatt MA, Higgins MC and Marton K (1989) Medical Decision Making. pp. 67-146. Butterworth: London
27. Swets JA (1988) Measuring the accuracy of diagnostic systems. Science 240: 1285-1293
28. Tsai JF, Chang WY, Jeng JE, Ho MS, Wang LY, Hsieh MY, Chen SC. Chuang WL Lin ZY and Tsai JH (1993) Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol 41: 296-300
29. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY and Tsai JH (1994a) Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver 14: 98-102
30. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY and Tsai JH (1994b) Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C. Br J Cancer 69: 1157-1159
31. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY and Tsai JH (1994c) Hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Chinese: a case control study. Int J Cancer 56: 619-621
32. Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY and Tsai JH (1995) Clinical evaluation of serum α-fetoprotein and circulating immune complexes as tumor markers of hepatocellular carcinoma. Br J Cancer 72: 442-446
33. Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY and Tsai JH (1996) Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer 73: 1498-1502
34. Yeh YC, Tsai JF, Chuang LY, Yeh HW, Tsai JH, Florine DL and Tam JP (1987) Elevation of transforming growth factor α and its relationship to the epidermal growth factor and α-fetoprolein levels in patients with hepatocellular carcinoma. Cancer Res 47: 896-901